Anna Törner: The clinical trial – Periscope to reality

What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.

Mavatar AB

From powder to implant

Quality assurance for additively manufactured implants.

AstraZeneca to use American AI platform for cancer trials

In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.

Reveal the Structures and Functions of Life

Super-resolution microscopes from ZEISS.

Genterapi gav hörsel till barn med medfödd dövhet – elva av tolv förbättrades

Elva av tolv barn med medfödd dövhet uppvisade förbättringar i en studie där Regenerons genterapi mot ärftlig hörselnedsättning prövades. Nu planerar det amerik...

Ny rapport: Små bolag lyfter svensk läkemedelsutveckling

Sveriges läkemedelsforskning fortsätter att gå starkt framåt, enligt en ny rapport från Sweden Bio. Landets projekt blir både fler och vassare – med småbolagen i spetsen.

Ingrid Lönnstedt: ”The confidence interval and its width”

Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.

Standardisation in automation

B. Braun Melsungen had a great idea and implemented it throughout the plant. Production for infusion solutions was to be largely standardised. B. Braun hoped th...

Anna Törner: Yes, I Am Sick, But Not Weak

”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...

SupraCube - In life Science

Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2026)

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

Lovande resultat för Lillys fetmapiller – skapar börsvågor

Eli Lillys viktminskningspiller överträffar förväntningarna i en fas III-studie och visar resultat i nivå med injicerbara läkemedel som Ozempic. Nyheten fick ak...

Takeover bid is being completed – Japanese company acquires Calliditas

Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...

What will be the next big hype after obesity? – An expert panel highlighted their top picks

What will be the next big trend in life science? Everything from Alzheimer’s, Crispr and Omics were highlighted when the issue was debated at this year’s major ...

Save the dates: ZEISS Quality Innovation Summit, October 22-24

Embark on a journey to the future of metrology.

The investor: “The major common diseases are hot again”

She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...

Snabbtest för halsfluss gav 40 procent falskt positiva svar

Ett snabbtest mot halsfluss har visat sig ge en mycket hög andel falskt positiva svar. Nu uppmanar företaget bakom testet vårdgivare att kassera berörda partier av produkten.

Healthcare study: Alzheimer’s blood test shows high accuracy

A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.

Life Science Sweden´s international issue is on its way

A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.

Catalent kapar bort 350 tjänster inom genterapi

CDMO-bolaget Catalent säger upp 350 av sina anställda inom genterapiproduktion i USA.

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.